Randomized trial of paroxetine in end-stage COPD

Lacasse, Yves; Beaudoin, Luc P.; Rousseau, L; Maltais, François

doi:10.4081/monaldi.2004.692

Cited by 95 publications

(61 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Negative effects of SSRIs on lung function in depressed patients with COPD do not appear to be a major problem. In the case of paroxetine, no significant changes in lung function were found [58]; respiratory symptoms did not worsen and dyspnoea slightly improved [57].…”

Section: Effects Of Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 87%

“…Overall, the available studies did not have the statistical power to detect superiority of SSRI over placebo [55][56][57][58]. In addition, the drop-out rates in these trials were high (21-50%), and a variety of depression rating scales was used (table 4) [10], Frustration with multiple medications and the fear of side-effects have been discussed as the reasons for high dropout rates for depressed COPD patients reported in these antidepressant trials [10].…”

Section: Effects Of Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Depression and suicidality in COPD: understandable reaction or independent disorders?

Hegerl

Mergl

2014

European Respiratory Journal

View full text Add to dashboard Cite

Both depression and chronic obstructive pulmonary disease (COPD) are prevalent, severe and often comorbid disorders. There is a risk of undertreatment for depression in patients with COPD as depressive symptoms, including suicidal tendencies, can erroneously be conceptualised as an understandable reaction to COPD and not as signs of an independent depressive disorder. In this context, the comorbidity rates of COPD and depression, the risk of suicidal behaviour in patients with COPD, and the evidence base for pharmaco-and psychotherapy in these patients are reviewed.Because symptoms of depression and COPD overlap it remains unclear how far the prevalence of major depression in COPD exceeds that in the general population. The suicide risk appears to be increased in COPD. Methodological studies providing evidence for the antidepressant efficacy of antidepressants or psychotherapy in patients with COPD are lacking. Recommendations for clinicians on how to separate depression from an understandable reaction to COPD are provided.Given the profound effects of depression on quality of life, life expectancy, COPD prognosis and suicide risk it is important to carefully diagnose and treat depression in patients with COPD according to national guidelines. @ERSpublications Comorbid depression has profound effects on COPD prognosis and should not be seen as understandable reaction to COPD

show abstract

Section: Effects Of Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 87%

Section: Effects Of Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Depression and suicidality in COPD: understandable reaction or independent disorders?

Hegerl

Mergl

2014

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…A number of other pharmacologic agents, including anxiolytics (251)(252)(253), antidepressants (254), phenothiazines (237,255), indomethacin (256,257), inhaled topical anesthetics (258,259), nitrous oxide (260), and sodium bicarbonate (261), have been found to be ineffective or lack sufficient data to recommend their use (247).…”

Section: Treatmentmentioning

confidence: 99%

An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea

Parshall¹,

Schwartzstein²,

Adams³

et al. 2012

Am J Respir Crit Care Med

1,475

1,328

View full text Add to dashboard Cite

“…Studies with the selective serotonin reuptake inhibitors fluoxetine and paroxetine were unsuccessful in COPD patients [147,148]. These studies identified the difficulties in treating frail and elderly COPD patients with antidepressants.…”

Section: Breathed Mixturesmentioning

confidence: 99%

Nonpharmacological treatment and relief of symptoms in COPD

Clini

Ambrosino²

2008

European Respiratory Journal

View full text Add to dashboard Cite

Evidence-based guidelines for chronic obstructive pulmonary disease (COPD) have recently been developed.Nonpharmacological treatments have evolved rapidly as an essential part of COPD therapy. They are especially important as complementary interventions in severe or very severe disease, when there is loss in function, a reduction in quality of life and when psychological impairments further complicate the disease.The present article discusses the most used nonpharmacological treatments for severe COPD patients (rehabilitation, long-term oxygen therapy, surgery, noninvasive positive pressure ventilation and supportive nutrition) and their evidence-based usefulness in promoting strategies that relieve symptoms.All of these interventions are used during end-stage disease, to promote self-efficacy, relieve symptoms and prevent further deterioration. These therapeutic options support physicians and allied professionals in improving symptom management for their patients.

show abstract

Randomized trial of paroxetine in end-stage COPD

Cited by 95 publications

References 31 publications

Depression and suicidality in COPD: understandable reaction or independent disorders?

Depression and suicidality in COPD: understandable reaction or independent disorders?

An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea

Nonpharmacological treatment and relief of symptoms in COPD

Contact Info

Product

Resources

About